Invictus Therapeutics
West Warwick
About Invictus Therapeutics
Invictus Therapeutics develops next-generation insulin analogs for use in insulin pumps and automated insulin delivery systems. The company builds on research from the lab of Michel Weiss, MD, PhD, MBA, translating long-term academic work into clinical-stage assets. Its programs focus on serving insulin-dependent people with diabetes, addressing needs in pharmacokinetics, safety, and usability. Invictus Therapeutics integrates scientific, clinical, and manufacturing capabilities to advance its insulin analog portfolio toward human studies.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Last round: Grant (Jan 2026)
- Website: invictustx.com
- Phone: [email protected]
Industries & Categories
Biopharma, Biotechnology, Clinical Trials, Diabetes, Health Care
Social Profiles
Canonical: https://fsome.com/organization/invictus-therapeutics-185197 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.